Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2023 | 13482 | 1.600 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5388 | 0.950 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1765 | 0.720 |
Why?
|
| Thoracic Neoplasms | 1 | 2022 | 268 | 0.680 |
Why?
|
| Pneumothorax | 1 | 2022 | 393 | 0.630 |
Why?
|
| Pyrimidinones | 1 | 2021 | 384 | 0.600 |
Why?
|
| Thyroid Diseases | 1 | 2021 | 385 | 0.590 |
Why?
|
| Coronavirus | 1 | 2020 | 155 | 0.580 |
Why?
|
| Pyridones | 1 | 2021 | 817 | 0.490 |
Why?
|
| Spiritual Therapies | 1 | 2014 | 60 | 0.430 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3111 | 0.400 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3233 | 0.400 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 294 | 0.360 |
Why?
|
| Immunotherapy | 2 | 2021 | 4746 | 0.300 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 4213 | 0.300 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 8037 | 0.290 |
Why?
|
| Steroids | 2 | 2021 | 934 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11858 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 9237 | 0.250 |
Why?
|
| Mutation | 6 | 2023 | 30208 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 5695 | 0.230 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 13634 | 0.220 |
Why?
|
| Ifosfamide | 1 | 2023 | 233 | 0.210 |
Why?
|
| Pandemics | 2 | 2020 | 8724 | 0.210 |
Why?
|
| Nuclear Proteins | 4 | 2023 | 5791 | 0.200 |
Why?
|
| Neoplasms | 5 | 2021 | 22336 | 0.180 |
Why?
|
| Palliative Care | 1 | 2014 | 3639 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2825 | 0.150 |
Why?
|
| Humans | 32 | 2023 | 766000 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 6361 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 5454 | 0.130 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 213 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 562 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 429 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1623 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 59493 | 0.120 |
Why?
|
| Transcription Factors | 4 | 2023 | 12128 | 0.110 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 384 | 0.110 |
Why?
|
| Quality of Life | 1 | 2014 | 13463 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2313 | 0.100 |
Why?
|
| Drug Approval | 1 | 2019 | 820 | 0.100 |
Why?
|
| Aged | 7 | 2023 | 171161 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1592 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 594 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 453 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1673 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 2015 | 657 | 0.090 |
Why?
|
| California | 1 | 2014 | 1435 | 0.080 |
Why?
|
| Middle Aged | 6 | 2023 | 223025 | 0.080 |
Why?
|
| Genomics | 2 | 2022 | 5924 | 0.080 |
Why?
|
| Survival Rate | 1 | 2023 | 12821 | 0.080 |
Why?
|
| Pneumonia | 1 | 2021 | 2158 | 0.080 |
Why?
|
| Radiology | 1 | 2022 | 2105 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2014 | 1140 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 81542 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4047 | 0.070 |
Why?
|
| Focus Groups | 1 | 2014 | 1459 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 1961 | 0.070 |
Why?
|
| Adult | 6 | 2023 | 223106 | 0.070 |
Why?
|
| Male | 7 | 2023 | 363855 | 0.070 |
Why?
|
| Female | 8 | 2023 | 396158 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5334 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 6961 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2023 | 3436 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 39233 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 10804 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 385 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 65199 | 0.040 |
Why?
|
| Chromosomes | 1 | 2023 | 578 | 0.040 |
Why?
|
| Prognosis | 4 | 2023 | 29904 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 24272 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 573 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2023 | 1058 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 20698 | 0.040 |
Why?
|
| Anxiety | 1 | 2014 | 4671 | 0.040 |
Why?
|
| New York City | 1 | 2021 | 736 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2023 | 852 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 14747 | 0.040 |
Why?
|
| Young Adult | 1 | 2023 | 59857 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 1775 | 0.030 |
Why?
|
| Cisplatin | 1 | 2022 | 1654 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 1609 | 0.030 |
Why?
|
| Child | 1 | 2023 | 80567 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 88808 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2021 | 1592 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 9064 | 0.030 |
Why?
|
| Depression | 1 | 2014 | 8229 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 2838 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2015 | 1079 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 576 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 17070 | 0.030 |
Why?
|
| Histones | 1 | 2023 | 2591 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2021 | 1945 | 0.030 |
Why?
|
| Chromatin | 1 | 2023 | 2980 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 4342 | 0.020 |
Why?
|
| United States | 1 | 2019 | 72916 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 21072 | 0.020 |
Why?
|
| Mice | 3 | 2023 | 81821 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3942 | 0.020 |
Why?
|
| Heart | 1 | 2021 | 4416 | 0.020 |
Why?
|
| Time Factors | 2 | 2021 | 40100 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2530 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 10089 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 4886 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8524 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 4262 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9378 | 0.020 |
Why?
|
| Animals | 3 | 2023 | 168775 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 8290 | 0.010 |
Why?
|
| Zebrafish | 1 | 2015 | 3035 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 13400 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13613 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 17597 | 0.010 |
Why?
|
| Lung | 1 | 2021 | 10060 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11202 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7423 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 36545 | 0.000 |
Why?
|
Concepts
(117)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(36)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_